Valuation: Castle Biosciences, Inc.

Market Cap 741M 652M 607M 557M 1.05B 71.09B 1.06B 7.21B 2.82B 35.1B 2.78B 2.72B 121B P/E 2026 *
-17.3x
P/E 2027 * -25.5x
Enterprise Value 741M 652M 607M 557M 1.05B 71.09B 1.06B 7.21B 2.82B 35.1B 2.78B 2.72B 121B EV / Sales 2026 *
2.1x
EV / Sales 2027 * 1.89x
Free-Float
97.27%
Yield 2026 *
-
Yield 2027 * -
1 day-0.99%
1 week+2.28%
Current month+2.47%
1 month+0.58%
3 months-2.16%
6 months-42.95%
Current year-37.17%
1 week 23.77
Extreme 23.77
25.62
1 month 22.46
Extreme 22.46
25.62
Current year 17.72
Extreme 17.722
44.28
1 year 14.59
Extreme 14.59
44.28
3 years 12.07
Extreme 12.07
44.28
5 years 9.26
Extreme 9.2601
78.58
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 2007-08-31
Director of Finance/CFO 56 2017-11-30
Chief Tech/Sci/R&D Officer - 2021-06-30
Director TitleAgeSince
Director/Board Member 64 2007-08-31
Chairman 64 2014-08-31
Director/Board Member 70 2018-12-05
Date Insider Type Main position Quantity % Market Cap.
7/14/26 Fiscal year

Founder

5,272 0.0174%
7/1/26 Fiscal year

Founder

22,264 0.0734%
7/1/26 Sell

Chief Operating Officer

-8,586 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
-0.99%+2.28%+52.08%+54.29% 741M
-1.26%-1.76%+227.49%+288.85% 19.29B
-1.91%-1.49%-44.43%-29.44% 9.49B
+3.06%+3.48%+48.13%+26.41% 7.03B
-0.76%+6.25%+225.44%-24.36% 5.83B
-2.79%+0.56%-17.77%-22.08% 5.45B
+7.13%-0.14%+83.94%+104.23% 4.48B
+0.71%+0.45%-47.09% - 4.42B
+0.09%-0.36%-25.54%-33.68% 4.04B
+1.43%-2.18%-20.82%-44.64% 2.69B
Average +0.48%-0.51%+48.14%+35.51% 6.35B
Weighted average by Cap. -0.03%-0.66%+87.76%+92.58%

Financials

2026 *2027 *
Net sales 352M 310M 288M 265M 497M 33.78B 504M 3.43B 1.34B 16.68B 1.32B 1.29B 57.66B 393M 345M 322M 295M 554M 37.68B 562M 3.82B 1.49B 18.61B 1.47B 1.44B 64.31B
Net income -43.46M -38.21M -35.57M -32.66M -61.34M -4.17B -62.15M -423M -165M -2.06B -163M -160M -7.11B -26.06M -22.91M -21.32M -19.58M -36.77M -2.5B -37.26M -253M -98.99M -1.23B -97.82M -95.71M -4.26B
Net Debt - -
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
942
Date Price Change Volume
26-07-27 US$24.44 -0.99% 291,638
26-07-24 US$24.69 -3.12% 408,990
26-07-23 US$25.48 +2.70% 407,874
26-07-22 US$24.81 +1.22% 437,921
26-07-21 US$24.51 +2.57% 326,248
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.44USD
Average target price
42.78USD
Spread / Average Target
+75.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSTL Stock